Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM621 in healthy volunteers and COVID-19 patients
NCT04582318Phase 2Terminated
- Sponsor
- NGM Biopharmaceuticals
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ngm621 in coronavirus disease 2019 (COVID-19), sponsored by NGM Biopharmaceuticals. Started Nov 2020; status: terminated.
02
Drugs
ngm621
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04582318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04582318.